UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With more than 7500 employees in approximately 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules and no major patient expiration in the next decade; - More than 25% of 2015 revenue reinvested into Research & Development - 2015 Key Financials: €3.88B global revenue Specialties: Neurology, Immunology
Show more
Anderlecht, BE
Size (employees)
7,563 (est)
UCB was founded in 1928 and is headquartered in Anderlecht, BE
Report incorrect company information

UCB Office Locations

UCB has an office in Anderlecht
Anderlecht, BE (HQ)
60 Allée de la Recherche
Show all (1)
Report incorrect company information

UCB Financials and Metrics

UCB Financials

Market capitalization (23-Oct-2017)

13.3 b

Closing share price (23-Oct-2017)

UCB's current market capitalization is $13.3 b.
Show all financial metrics

UCB Operating Metrics

FY, 2015FY, 2016

Patients Reached

1.85 m2.59 m
Show all operating metrics
Report incorrect company information

UCB News and Updates

AbbVie, Allergan, Roche could join Biogen, UCB in Acorda hunt: analyst

Neurology-focused Biogen and UCB are already rumored to be eyeing an Acorda buyout. But one analyst thinks a host of other major players could join their ranks.

Acorda draws buyout interest from neuro-focused Biogen, UCB: report

Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.

Parkinson’s Treatment 2017 Global Market Outlook,Research,Trends and Forecast to 2023

WiseGuyReports.Com Publish a New Market Research Report On - “Parkinson’s Treatment 2017 Global Market Outlook,Research,Trends and Forecast to 2023”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Partners, UCB to tailor digital health solutions for epilepsy treatment

The high-profile provider and the biopharmaceutical firm seek to provide better connectivity between patients, providers and payers.
Report incorrect company information